Recent clinical advances underscored that elimination of tumor-induced immunosuppression is prerequisite for successful therapy of advanced human cancers. The myeloid-derived suppressor cells (MDSCs) are one of the major populations limiting T cell-mediated antitumor immune responses in late-stage solid tumors, such as castration-resistant prostate cancers (CRPCs). Targeting MDSCs proved challenging due to their heterogeneity and phenotypic similarities with other myeloid cell lineages. Here, we identify a population of granulocytic MDSCs, which accumulate in patients\' blood during progression of prostate cancer from localized to metastatic disease. The CRPC-associated MDSCs potently inhibit proliferation, IFN-γ and Granzyme-B production in autologous CD8^+^T cells. Importantly, the MDSCs in blood and in lymph nodes of CRPC patients show high levels of activated STAT3 transcription factor, which is a crucial immune checkpoint regulator. We previously generated an original method to silence genes specifically in TLR9^+^myeloid cells using CpG-siRNA conjugates \[[@B1],[@B2]\]. Now, we demonstrate that the CpG-*STAT3*siRNA is also effectively internalized by human MDSCs and induces *STAT3*silencing without the need for transfection reagents. Our further studies demonstrated that two-pronged TLR9-activation/STAT3-blocking by CpG-*STAT3*siRNA inhibits immunosuppressive effects of CRPC-MDSCs on CD8^+^T cells, while both TLR9 triggering or STAT3 inhibition alone have only minimal effects. The reversal of MDSC immunosuppression by CpG-*STAT3*siRNA results from reduced expression and enzymatic activity of Arginase I, a downstream STAT3 target gene. Overall, our study demonstrates the feasibility of overcoming immunosuppression in CRPC patients using CpG-*STAT3*siRNA strategy to alleviate effects of MDSCs. We anticipate that our strategy to reverse MDSC-mediated immunosuppression without depleting myeloid cell populations will generate safer and more effective immunotherapy for late-stage, metastatic prostate cancers and potentially other solid tumors.
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